Packages of the weight-loss drug Wegovy from the pharmaceutical firm Novo Nordisk lie on the gross sales counter in a Danish pharmacy.
Stefan Trumpf | Image Alliance | Getty Photos
Shares of Danish drugmaker Novo Nordisk soared Tuesday, after late-stage trial information confirmed that its weight problems drug Wegovy decreased the danger of main cardiovascular occasions equivalent to coronary heart assaults or strokes by 20%, in contrast with a placebo.
The outcomes of the carefully watched “SELECT” trial, which exceeded expectations, had been seen as a serious enhance for the corporate’s hopes of transferring past Wegovy’s picture as a “vainness drug.”
Shares of Novo Nordisk rose almost 16% throughout mid-morning offers, earlier than paring positive aspects. The inventory was final seen buying and selling 14% increased at 1:35 p.m. London time (8:35 a.m. ET).
The double-blind trial started virtually 5 years in the past and concerned greater than 17,600 adults with established heart problems who had been obese or suffered from weight problems, however had no prior historical past of diabetes.
The headline outcomes present that the weekly injection of semaglutide 2.4 mg achieved its main objection of decreasing the danger of cardiovascular occasions, equivalent to coronary heart assaults or strokes, by 20% in contrast with a placebo. Wegovy comprises 2.4 mg of semaglutide.
Buyers and analysts had advised Reuters {that a} danger discount of between 15% and 17% can be interpreted as a optimistic consequence for the blockbuster weight reduction drug.
Martin Holst Lange, govt vp for improvement at Novo Nordisk, stated that the outcomes confirmed that the corporate’s weight problems drug “has the potential to vary how weight problems is regarded and handled.”
“Individuals dwelling with weight problems have an elevated danger of heart problems however up to now, there aren’t any accepted weight administration medicines confirmed to ship efficient weight administration whereas additionally decreasing the danger of coronary heart assault, stroke or cardiovascular loss of life,” Holst Lange stated in a press release.
“Subsequently, we’re very excited concerning the outcomes from SELECT exhibiting that semaglutide 2.4 mg reduces the danger of cardiovascular occasions.”
The corporate stated it expects to file for regulatory approvals of a label indication growth for Wegovy within the U.S. and European Union this 12 months.
Emily Subject, head of European prescription drugs fairness analysis at Barclays, advised CNBC final month that the outcomes of Novo Nordisk’s SELECT trial amounted to an vital litmus check for the well being trade.
Within the occasion that the drug was discovered to have wider-reaching functions, together with cardiovascular advantages, Subject stated that it was extra doubtless that it may very well be adopted beneath mainstream health-care insurance policies.
Public well being companies “do not wish to pay for it, if it will not deal with underlying well being circumstances,” she stated.
The detailed outcomes from the SELECT trial might be introduced at a scientific convention later within the 12 months, Novo Nordisk stated, with out totally disclosing the timeline.
— CNBC’s Karen Gilchrist contributed to this report.
